View ValuationCochlear 将来の成長Future 基準チェック /06Cochlear利益と収益がそれぞれ年間8.1%と4.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に19% 7.8%なると予測されています。主要情報8.1%収益成長率7.75%EPS成長率Medical Equipment 収益成長0%収益成長率4.5%将来の株主資本利益率19.02%アナリストカバレッジGood最終更新日18 May 2026今後の成長に関する最新情報お知らせ • Feb 16+ 1 more updateCochlear Limited Provides Earnings Outlook for the Year 2023Cochlear Limited provided earnings outlook for the year 2023. For the period, the company continue to expect to deliver underlying net profit of $290-305 million, a 5-10% increase on FY22 underlying net profit, an increase of 8-13% when adjusted for the increase in cloud computing-related expenses.すべての更新を表示Recent updatesお知らせ • Feb 13Cochlear Limited Announces an Interim Franked Ordinary Dividend for the Six Months Ended December 31, 2025, Payable on 13 April 2026Cochlear Limited announced an interim franked ordinary dividend of AUD 2.15 per share has been determined for the six months ended December 31, 2025, in line with last year and representing a payout of 72% of underlying net profit. The interim dividend is franked at 85%. The ex-dividend date is 19 March 2026. The record date for calculating dividend entitlements is 20 March 2026 with the interim dividend expected to be paid on 13 April 2026. The ex-date is March 19, 2026, and the record date is March 20, 2026.お知らせ • Jan 08Cochlear Announces Availability of Nucleus Nexa System to Us Military VeteransCochlear announced that the Nucleus®? Nexa®? System is now available to eligible US military veterans at VA clinics nationwide. This milestone ensures that veterans with hearing loss have access to Cochlear's most innovative hearing technologies, designed to deliver smarter, more connected hearing experiences. The Nucleus Nexa System is the world's first smart cochlear implant system. The features include upgradeable firmware, internal memory, and with the Power Compact rechargeable battery, is the smallest and lightest sound processor with all day battery life on the market. Paired with the Nucleus 8 Nexa or Kanso®? 3 Nexa sound processors, the system offers intelligent performance that adjusts in real time to changing environments, helping users hear with clarity and comfort.お知らせ • Sep 22Cochlear Limited Announces Franked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on October 13, 2025Cochlear Limited announced franked ordinary dividend of AUD 2.15000000 per share for the six months ended June 30, 2025, payable on October 13, 2025. Record Date is September 19, 2025. Ex Date is September 18, 2025.お知らせ • Aug 15+ 1 more updateCochlear Limited to Report First Half, 2026 Results on Feb 13, 2026Cochlear Limited announced that they will report first half, 2026 results on Feb 13, 2026お知らせ • Aug 12Cochlear Limited, Annual General Meeting, Oct 23, 2025Cochlear Limited, Annual General Meeting, Oct 23, 2025. Location: hybrid meeting, Australiaお知らせ • Jul 08Cochlear Limited Launches Smart Cochlear Implant SystemCochlear Limited announced the U.S Food and Drug Administration (FDA) approval of the Cochlear™? Nucleus®? Nexa™? System - the world's first and only smart cochlear implant system. Until now, recipients of cochlear implants have been limited to accessing new technology through the external part of their cochlear implant system - the sound processor - and have typically needed a new sound processor to fully experience the benefits of new technology. The new smart Nexa System has upgradeable implant firmware, which for the first time will enable Cochlear recipients to access future innovation through both their implant and sound processor. Recipients will now have access to their best possible hearing experience with both implant and sound processor updates. The Nucleus Nexa System builds upon Cochlear's portfolio of electrodes, which are designed to optimize the electrode-neural interface and protect cochlear health for a lifetime of hearing performance and opens the door to even greater hearing potential for patients into the future.お知らせ • Jun 03Cochlear Limited Introduces the Baha®? 7 Sound Processor and Baha SoundBandCochlear Limited announced the commercial release of the new Cochlear™? Baha®? 7 Sound Processor and the new non-surgical Baha SoundBand™. Cochlear's bone conduction hearing solutions are designed to improve hearing outcomes for children and adults with conductive hearing loss, mixed hearing loss and single-sided deafness (SSD). The Baha 7 Sound Processor builds upon the same great hearing performance of its predecessor while advancing Cochlear's connectivity. The Baha 7 Sound Processor boasts a 55 db HL fitting range in a small form factor, offering powerful hearing without compromising on discretion. With new Bluetooth LE Audio and Auracast broadcast audio compatibility, the Baha 7 Sound Processor leads the hearing implant industry in streaming technology. As more venues adopt Auracast technology, Baha 7 Sound Processor recipients can access audio streams in places like theaters, concert halls, lecture halls and airports, through an LE Audio-enabled smartphone. The Baha 7 Sound processor is also able to stream directly from any compatible Apple® and Android™ device, as well as a range of wireless accessories. non-surgical Baha Start portfolio now includes the Baha 7 Sound Processor and the new Baha SoundBand. Baha Start is designed to help babies and young children experience the fullness of clear, rich and natural sound as early as possible. Early access to sound is critical to helping children learn and develop on par with their hearing peers. The new SoundBand features a slimmer band with improved adjustability, a lower profile, moveable connector discs and more color options to help young children be as comfortable and confident as possible. The Baha Smart App®? and Baha Fitting Software 7 also have new features aimed to help parents and clinicians treat children for the best possible hearing outcomes. The Baha 7 sound Processor and Baha SoundBand will be available in the United States in late summer 2025.お知らせ • Feb 15Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended December 31, 2024, Payable on April 14, 2025Cochlear Limited announced ordinary dividend of AUD 2.15000000 per security for the period of six months ended December 31, 2024. Record date: March 21, 2025. Ex-date: March 20, 2025. Payment date: April 14, 2025.お知らせ • Sep 19+ 1 more updateStu Sayers to Appoint as President, Asia Pacific & Latin America of Cochlear Limited, Effective from 1 January 2025Cochlear Limited announced that Stu Sayers, current CFO, will be appointed President, Asia Pacific & Latin America from 1 January 2025.お知らせ • Aug 17+ 1 more updateCochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024Cochlear Limited announced ordinary dividend of AUD 2.10000000 per security for the period of six months ended June 30, 2024. Ex Date is September 17, 2024; Record Date is September 18, 2024; Payment Date is October 10, 2024.お知らせ • Aug 15+ 2 more updatesCochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.Cochlear Limited (ASX:COH) announces a share repurchase program. Under the program, the company will repurchase up to AUD 75 million worth of its ordinary shares. The program will expire on August 28, 2025. As of August 15, 2024, the company has 65,494,231 shares in issue.お知らせ • Jul 30Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024Cochlear Limited (Cochlear) announced the appointment of Caroline Clarke to the Cochlear Board. Ms. Clarke's appointment as a Non-Executive Director will become effective on 2 September 2024. Ms. Clarke has more than 30 years of commercial experience, including 20 years of executive leadership roles at medical devices, medical equipment and healthcare services businesses in large global companies. Ms. Clarke was most recently CEO and Executive Vice President ASEAN Pacific for Philips, responsible for the overall strategy, business and management of the Health Systems and Consumer Personal Health businesses in 14 countries across the region. Caroline is an impressive, people-oriented business leader, driven by making a meaningful impact by improving lives and has demonstrable experience in partnering with leading healthcare institutions to deliver new solutions. Her rounded experience and skills will be invaluable to Cochlear and serve to further enhance the expertise of the Board. Ms. Clarke will become a member of the People and Culture Committee, the Product & Services Innovation Committee and the Nomination Committee. Ms. Clarke holds a bachelor's degree in Business Studies, is a graduate of the Harvard Business School's Advanced Management Program and the Australian Institute of Company Directors, and resides in Sydney, Australia.お知らせ • Jul 26Cochlear Limited Announces Executive ChangesCochlear Limited announced a number of changes to the executive team. Richard Brook will be stepping down as President, Europe and Middle East and Africa (EMEA) at the end of December 2024 after more than 20 years in the role. Richard has overseen a period of substantial growth for EMEA, with an eight-fold increase in revenue during that time. Anthony Bishop, current President, Asia Pacific & Latin America, will be appointed President, EMEA from 1 January 2025. Anthony was appointed President, Asia Pacific in July 2016 and took on responsibility for Latin America in June 2021. He has been responsible for the development and execution of the strategic direction for all its operations in Australia, Asia, the South Pacific and Latin America. Prior to Cochlear, Anthony spent 21 years at Johnson & Johnson Medical in various roles, including marketing, sales and general management around the world, including Managing Director, Johnson & Johnson Medical, Australia/New Zealand. Stu Sayers, current Chief Financial Officer, will be appointed President, Asia Pacific & Latin America from 1 January 2025. Stu was appointed as Chief Financial Officer in February 2021 and was previously President, Services since joining Cochlear in July 2016. Prior to Cochlear, Stu led Amazon's subsidiary Audible in Asia Pacific, as well as E*TRADE and Yahoo!7 in Australia and New Zealand. He previously held senior roles with ANZ and McKinsey.お知らせ • May 22+ 1 more updateCochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).Cochlear Limited (ASX:COH) agreed to acquire Oticon Medical A/s from Demant A/S (CPSE:DEMANT) for DKK 850 million on April 27, 2022. Of the total consideration of DKK 850 million, DKK 700 million will be paid in cash at closing and DKK 150 million within 18 months after closing. In 2021, Oticon realized revenue of DKK 512 million and Negative EBIT of DKK 117 million. Subject to regulatory approvals and other customary closing conditions and receipt of competition approval. The acquisition is conditional upon approval from each of the CMA, the Australian Competition and Consumer Commission and the European Commission. On October 11, 2022 the CMA launched its phase 1 merger investigation for the acquisition of Oticon Medical A/S. The transaction is expected to close in second half of 2022, following consultation of relevant workers’ councils. As of December 1, 2022, The ACCC has advised a provisional final decision date of March 16, 2023. As on December 7, 2022, The CMA’s competition concerns only relate to the supply of bone conduction solutions in the UK and do not relate to the supply of cochlear implants. Cochlear and Demant have until 13 December to submit undertakings to address the CMA’s competition concerns. As of December 20, 2022, Competition and Markets Authority decided to refer this Merger for a phase 2 investigation. As of April 20, 2023, CMA has provisionally found competition concerns as part of its in-depth investigation and has kept the deadline for submitting responses to the provisional findings as May 11, 2023. The CMA’s final report is expected by June 5, 2023. Cochlear awaits feedback from the Australian Competition and Consumer Commission and the European Commission as well as the outcome of the review by the French Foreign Direct Investment authority. As a result of the CMA’s findings, the transaction is no longer expected to close before June 30, 2023. As on June 22, 2023, following the report published by UK Competition and Markets Authority, Demant and Cochlear agreed to amend scope of the original transaction, involving the divestment of Demant’s Hearing Implants business, Oticon Medical, to Cochlear Limited. The amended transaction only involves Demant’s cochlear implants (CI) business, whereas the bone anchored hearing systems (BAHS) business is no longer part of the transaction and will thus remain with Demant for now. The UK Competition and Markets Authority published its final report that does not raise competition concerns and is permitted to proceed, subject to the CMA’s approval of the terms of all agreements related to the transfer of the CI business to Cochlear. As on August 2, 2023, CMA proposes to accept the attached proposed Final Undertakings; and proposed Final Undertakings seek to address the SLC identified in the Report and any adverse effects resulting from the SLC. As of August 15, 2023, the acquisition is expected to complete by end December 2023. AS of October 9, 2023, European Commission approved the acquisition of Oticon Medical. As of February 19, 2024, the acquisition is expected to complete by the end of June 2024. As of April 4, 2024, Australian Competition and Consumer Commission decided not to oppose the acquisition of Oticon Medical. Ash Chandhok Tiwari of Baker & Mckenzie LLP acted as legal; advisor to Cochlear. Cochlear Limited (ASX:COH) completed the acquisition of Oticon Medical A/s from Demant A/S (CPSE:DEMANT) on May 21, 2024. The transaction has got all the regulatory and customary closing conditions fulfilled.お知らせ • Apr 23Cochlear Limited Announces Company Secretary ChangesCochlear Limited announced the appointment of Ms Kristy Jo and Mr. Rob McGrory each as Company Secretary, effective 22 April 2024. These appointments follow the disclosure at the 2023 Annual General Meeting of the pending retirement of Mr. Ray Jarman as Company Secretary, which is effective 22 April 2024. Ms Jo is now the person responsible for communications with the ASX under Listing Rule 12.6.お知らせ • Apr 20Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-OldCochlear Limited obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™? Osia System from 12 years-old to 5-years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The Osia System is a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the innerear (cochlea). It is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. Now children as young as 5 will be able to have full access to the Osia System's unique technology that is optimized to deliver high power and clarity, especially in high-frequency sounds, which are important for hearing what others are saying. Adrian was diagnosed with hearing loss at age 4 and started with the Baha® Sound Processor with a Baha Softband before transitioning to the Osia System at age 6. The Osia System has been shown to provide clinically significant improvements in high frequency hearing for children.お知らせ • Aug 19Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 TCochlear Limited introduced its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The new Osia System offers the proven benefits as the current version: excellent hearing outcomes, ease of use, discreetness and reliability. With the introduction of the OSI300 Implant, it is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. This new patient benefit is made possible by combining the unique properties of the Osia System's Piezo Power™ transducer, which does not contain magnetic material, and the next generation in implant magnet technology. The OSI300 Implant is specifically designed to support access to MRI with no performance degradation after MRI exposure, as there is nothing to be demagnetized as in an electromagnetic transducer. Unlike an axial magnet, which is found in most bone conduction implants and is unsuitable for a patient undergoing an MRI examination at 3.0 T, the OSI300 uses a diametric magnet that sits within a casing and rotates to align with the magnetic field of the MRI machine. The next generation of the Osia System will be available in clinics across the United States this fall and is currently being reviewed by Health Canada. Availability in other countries is subject to regulatory approvals.お知らせ • Aug 15Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024Cochlear Limited announced that they will report fiscal year 2024 results on Aug 15, 2024お知らせ • Jul 18Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023Cochlear Limited announced that Non-executive Director Andrew Denver has advised his intention to retire from the Cochlear Board at the end of the next annual general meeting which will be held on 17 October 2023. Mr. Andrew Denver joined the Cochlear Board on 1 February 2007 and has served as a member of the Audit and Risk, Medical Science, Nomination and Product & Services Innovation Committees.Upcoming Dividend • Mar 14Upcoming dividend of AU$1.55 per share at 1.3% yieldEligible shareholders must have bought the stock before 21 March 2023. Payment date: 14 April 2023. Payout ratio is a comfortable 68% and the cash payout ratio is 76%. Trailing yield: 1.3%. Lower than top quartile of Mexican dividend payers (6.0%). Lower than average of industry peers (1.8%).Recent Insider Transactions • Mar 08Independent Non-Executive Director recently bought Mex$358k worth of stockOn the 6th of March, Michael J. Del Prado bought around 132 shares on-market at roughly Mex$2,714 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Mex$6.3m more in shares than they have sold in the last 12 months.お知らせ • Feb 16+ 1 more updateCochlear Limited Provides Earnings Outlook for the Year 2023Cochlear Limited provided earnings outlook for the year 2023. For the period, the company continue to expect to deliver underlying net profit of $290-305 million, a 5-10% increase on FY22 underlying net profit, an increase of 8-13% when adjusted for the increase in cloud computing-related expenses.お知らせ • Nov 16Cochlear Limited, Annual General Meeting, Oct 17, 2023Cochlear Limited, Annual General Meeting, Oct 17, 2023.Recent Insider Transactions • Oct 25Non-Executive Independent Director recently bought Mex$315k worth of stockOn the 24th of October, Karen Lee Penrose bought around 128 shares on-market at roughly Mex$2,464 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Mex$597k. Insiders have collectively bought Mex$3.2m more in shares than they have sold in the last 12 months.Upcoming Dividend • Sep 15Upcoming dividend of AU$1.45 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 17 October 2022. Payout ratio is a comfortable 68% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Mexican dividend payers (6.4%). Lower than average of industry peers (1.7%).Recent Insider Transactions • Aug 26Independent Non-Executive Director recently bought Mex$592k worth of stockOn the 24th of August, Michael Daniell bought around 200 shares on-market at roughly Mex$2,960 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Mex$1.4m more in shares than they have sold in the last 12 months.Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$4.40 (vs AU$4.93 in FY 2021)Full year 2022 results: EPS: AU$4.40 (down from AU$4.93 in FY 2021). Revenue: AU$1.65b (up 10% from FY 2021). Net income: AU$289.1m (down 11% from FY 2021). Profit margin: 18% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 5.4%, compared to a 18% growth forecast for the Medical Equipment industry in Mexico.業績と収益の成長予測BMV:COH N - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20282,591379370480146/30/20272,420327322434156/30/20262,3262522503711512/31/20252,339345166265N/A9/30/20252,341367150251N/A6/30/20252,343389135238N/A3/31/20252,326380193290N/A12/31/20242,309371251342N/A9/30/20242,272364275365N/A6/30/20242,236357299389N/A3/31/20242,193354317410N/A12/31/20232,149350335430N/A9/30/20232,043326301396N/A6/30/20231,936301267362N/A3/31/20231,824281263352N/A12/31/20221,713261259341N/A9/30/20221,681275279359N/A6/30/20221,648289299377N/A3/31/20221,612273266340N/A12/31/20211,575257233304N/A9/30/20211,536291216285N/A6/30/20211,498324199265N/A3/31/20211,40382-5234N/A12/31/20201,308-160-302-198N/A9/30/20201,314-199-295-178N/A6/30/20201,321-238-288-158N/A3/31/20201,40034-8050N/A12/31/20191,479306128259N/A9/30/20191,453291N/A277N/A6/30/20191,427277N/A296N/A3/31/20191,422270N/A313N/A12/31/20181,418264N/A330N/A9/30/20181,391255N/A294N/A6/30/20181,364246N/A258N/A3/31/20181,329234N/A254N/A12/31/20171,294223N/A250N/A9/30/20171,274223N/A255N/A6/30/20171,254224N/A260N/A3/31/20171,218215N/A237N/A12/31/20161,182206N/A214N/A9/30/20161,156198N/A199N/A6/30/20161,131189N/A185N/A3/31/20161,088179N/A179N/A12/31/20151,045168N/A172N/A9/30/2015986157N/A181N/A6/30/2015926146N/A189N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: COH Nの予測収益成長率 (年間8.1% ) は 貯蓄率 ( 9% ) を下回っています。収益対市場: COH Nの収益 ( 8.1% ) MX市場 ( 9.1% ) よりも低い成長が予測されています。高成長収益: COH Nの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: COH Nの収益 ( 4.5% ) MX市場 ( 6.2% ) よりも低い成長が予測されています。高い収益成長: COH Nの収益 ( 4.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COH Nの 自己資本利益率 は、3年後には低くなると予測されています ( 19 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 23:15終値2026/02/27 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cochlear Limited 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26 アナリスト機関Saul HadassinBarrenjoey Markets Pty LimitedStuart RobertsBell PotterElisabeth Decou CliveBernstein23 その他のアナリストを表示
お知らせ • Feb 16+ 1 more updateCochlear Limited Provides Earnings Outlook for the Year 2023Cochlear Limited provided earnings outlook for the year 2023. For the period, the company continue to expect to deliver underlying net profit of $290-305 million, a 5-10% increase on FY22 underlying net profit, an increase of 8-13% when adjusted for the increase in cloud computing-related expenses.
お知らせ • Feb 13Cochlear Limited Announces an Interim Franked Ordinary Dividend for the Six Months Ended December 31, 2025, Payable on 13 April 2026Cochlear Limited announced an interim franked ordinary dividend of AUD 2.15 per share has been determined for the six months ended December 31, 2025, in line with last year and representing a payout of 72% of underlying net profit. The interim dividend is franked at 85%. The ex-dividend date is 19 March 2026. The record date for calculating dividend entitlements is 20 March 2026 with the interim dividend expected to be paid on 13 April 2026. The ex-date is March 19, 2026, and the record date is March 20, 2026.
お知らせ • Jan 08Cochlear Announces Availability of Nucleus Nexa System to Us Military VeteransCochlear announced that the Nucleus®? Nexa®? System is now available to eligible US military veterans at VA clinics nationwide. This milestone ensures that veterans with hearing loss have access to Cochlear's most innovative hearing technologies, designed to deliver smarter, more connected hearing experiences. The Nucleus Nexa System is the world's first smart cochlear implant system. The features include upgradeable firmware, internal memory, and with the Power Compact rechargeable battery, is the smallest and lightest sound processor with all day battery life on the market. Paired with the Nucleus 8 Nexa or Kanso®? 3 Nexa sound processors, the system offers intelligent performance that adjusts in real time to changing environments, helping users hear with clarity and comfort.
お知らせ • Sep 22Cochlear Limited Announces Franked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on October 13, 2025Cochlear Limited announced franked ordinary dividend of AUD 2.15000000 per share for the six months ended June 30, 2025, payable on October 13, 2025. Record Date is September 19, 2025. Ex Date is September 18, 2025.
お知らせ • Aug 15+ 1 more updateCochlear Limited to Report First Half, 2026 Results on Feb 13, 2026Cochlear Limited announced that they will report first half, 2026 results on Feb 13, 2026
お知らせ • Aug 12Cochlear Limited, Annual General Meeting, Oct 23, 2025Cochlear Limited, Annual General Meeting, Oct 23, 2025. Location: hybrid meeting, Australia
お知らせ • Jul 08Cochlear Limited Launches Smart Cochlear Implant SystemCochlear Limited announced the U.S Food and Drug Administration (FDA) approval of the Cochlear™? Nucleus®? Nexa™? System - the world's first and only smart cochlear implant system. Until now, recipients of cochlear implants have been limited to accessing new technology through the external part of their cochlear implant system - the sound processor - and have typically needed a new sound processor to fully experience the benefits of new technology. The new smart Nexa System has upgradeable implant firmware, which for the first time will enable Cochlear recipients to access future innovation through both their implant and sound processor. Recipients will now have access to their best possible hearing experience with both implant and sound processor updates. The Nucleus Nexa System builds upon Cochlear's portfolio of electrodes, which are designed to optimize the electrode-neural interface and protect cochlear health for a lifetime of hearing performance and opens the door to even greater hearing potential for patients into the future.
お知らせ • Jun 03Cochlear Limited Introduces the Baha®? 7 Sound Processor and Baha SoundBandCochlear Limited announced the commercial release of the new Cochlear™? Baha®? 7 Sound Processor and the new non-surgical Baha SoundBand™. Cochlear's bone conduction hearing solutions are designed to improve hearing outcomes for children and adults with conductive hearing loss, mixed hearing loss and single-sided deafness (SSD). The Baha 7 Sound Processor builds upon the same great hearing performance of its predecessor while advancing Cochlear's connectivity. The Baha 7 Sound Processor boasts a 55 db HL fitting range in a small form factor, offering powerful hearing without compromising on discretion. With new Bluetooth LE Audio and Auracast broadcast audio compatibility, the Baha 7 Sound Processor leads the hearing implant industry in streaming technology. As more venues adopt Auracast technology, Baha 7 Sound Processor recipients can access audio streams in places like theaters, concert halls, lecture halls and airports, through an LE Audio-enabled smartphone. The Baha 7 Sound processor is also able to stream directly from any compatible Apple® and Android™ device, as well as a range of wireless accessories. non-surgical Baha Start portfolio now includes the Baha 7 Sound Processor and the new Baha SoundBand. Baha Start is designed to help babies and young children experience the fullness of clear, rich and natural sound as early as possible. Early access to sound is critical to helping children learn and develop on par with their hearing peers. The new SoundBand features a slimmer band with improved adjustability, a lower profile, moveable connector discs and more color options to help young children be as comfortable and confident as possible. The Baha Smart App®? and Baha Fitting Software 7 also have new features aimed to help parents and clinicians treat children for the best possible hearing outcomes. The Baha 7 sound Processor and Baha SoundBand will be available in the United States in late summer 2025.
お知らせ • Feb 15Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended December 31, 2024, Payable on April 14, 2025Cochlear Limited announced ordinary dividend of AUD 2.15000000 per security for the period of six months ended December 31, 2024. Record date: March 21, 2025. Ex-date: March 20, 2025. Payment date: April 14, 2025.
お知らせ • Sep 19+ 1 more updateStu Sayers to Appoint as President, Asia Pacific & Latin America of Cochlear Limited, Effective from 1 January 2025Cochlear Limited announced that Stu Sayers, current CFO, will be appointed President, Asia Pacific & Latin America from 1 January 2025.
お知らせ • Aug 17+ 1 more updateCochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024Cochlear Limited announced ordinary dividend of AUD 2.10000000 per security for the period of six months ended June 30, 2024. Ex Date is September 17, 2024; Record Date is September 18, 2024; Payment Date is October 10, 2024.
お知らせ • Aug 15+ 2 more updatesCochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.Cochlear Limited (ASX:COH) announces a share repurchase program. Under the program, the company will repurchase up to AUD 75 million worth of its ordinary shares. The program will expire on August 28, 2025. As of August 15, 2024, the company has 65,494,231 shares in issue.
お知らせ • Jul 30Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024Cochlear Limited (Cochlear) announced the appointment of Caroline Clarke to the Cochlear Board. Ms. Clarke's appointment as a Non-Executive Director will become effective on 2 September 2024. Ms. Clarke has more than 30 years of commercial experience, including 20 years of executive leadership roles at medical devices, medical equipment and healthcare services businesses in large global companies. Ms. Clarke was most recently CEO and Executive Vice President ASEAN Pacific for Philips, responsible for the overall strategy, business and management of the Health Systems and Consumer Personal Health businesses in 14 countries across the region. Caroline is an impressive, people-oriented business leader, driven by making a meaningful impact by improving lives and has demonstrable experience in partnering with leading healthcare institutions to deliver new solutions. Her rounded experience and skills will be invaluable to Cochlear and serve to further enhance the expertise of the Board. Ms. Clarke will become a member of the People and Culture Committee, the Product & Services Innovation Committee and the Nomination Committee. Ms. Clarke holds a bachelor's degree in Business Studies, is a graduate of the Harvard Business School's Advanced Management Program and the Australian Institute of Company Directors, and resides in Sydney, Australia.
お知らせ • Jul 26Cochlear Limited Announces Executive ChangesCochlear Limited announced a number of changes to the executive team. Richard Brook will be stepping down as President, Europe and Middle East and Africa (EMEA) at the end of December 2024 after more than 20 years in the role. Richard has overseen a period of substantial growth for EMEA, with an eight-fold increase in revenue during that time. Anthony Bishop, current President, Asia Pacific & Latin America, will be appointed President, EMEA from 1 January 2025. Anthony was appointed President, Asia Pacific in July 2016 and took on responsibility for Latin America in June 2021. He has been responsible for the development and execution of the strategic direction for all its operations in Australia, Asia, the South Pacific and Latin America. Prior to Cochlear, Anthony spent 21 years at Johnson & Johnson Medical in various roles, including marketing, sales and general management around the world, including Managing Director, Johnson & Johnson Medical, Australia/New Zealand. Stu Sayers, current Chief Financial Officer, will be appointed President, Asia Pacific & Latin America from 1 January 2025. Stu was appointed as Chief Financial Officer in February 2021 and was previously President, Services since joining Cochlear in July 2016. Prior to Cochlear, Stu led Amazon's subsidiary Audible in Asia Pacific, as well as E*TRADE and Yahoo!7 in Australia and New Zealand. He previously held senior roles with ANZ and McKinsey.
お知らせ • May 22+ 1 more updateCochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).Cochlear Limited (ASX:COH) agreed to acquire Oticon Medical A/s from Demant A/S (CPSE:DEMANT) for DKK 850 million on April 27, 2022. Of the total consideration of DKK 850 million, DKK 700 million will be paid in cash at closing and DKK 150 million within 18 months after closing. In 2021, Oticon realized revenue of DKK 512 million and Negative EBIT of DKK 117 million. Subject to regulatory approvals and other customary closing conditions and receipt of competition approval. The acquisition is conditional upon approval from each of the CMA, the Australian Competition and Consumer Commission and the European Commission. On October 11, 2022 the CMA launched its phase 1 merger investigation for the acquisition of Oticon Medical A/S. The transaction is expected to close in second half of 2022, following consultation of relevant workers’ councils. As of December 1, 2022, The ACCC has advised a provisional final decision date of March 16, 2023. As on December 7, 2022, The CMA’s competition concerns only relate to the supply of bone conduction solutions in the UK and do not relate to the supply of cochlear implants. Cochlear and Demant have until 13 December to submit undertakings to address the CMA’s competition concerns. As of December 20, 2022, Competition and Markets Authority decided to refer this Merger for a phase 2 investigation. As of April 20, 2023, CMA has provisionally found competition concerns as part of its in-depth investigation and has kept the deadline for submitting responses to the provisional findings as May 11, 2023. The CMA’s final report is expected by June 5, 2023. Cochlear awaits feedback from the Australian Competition and Consumer Commission and the European Commission as well as the outcome of the review by the French Foreign Direct Investment authority. As a result of the CMA’s findings, the transaction is no longer expected to close before June 30, 2023. As on June 22, 2023, following the report published by UK Competition and Markets Authority, Demant and Cochlear agreed to amend scope of the original transaction, involving the divestment of Demant’s Hearing Implants business, Oticon Medical, to Cochlear Limited. The amended transaction only involves Demant’s cochlear implants (CI) business, whereas the bone anchored hearing systems (BAHS) business is no longer part of the transaction and will thus remain with Demant for now. The UK Competition and Markets Authority published its final report that does not raise competition concerns and is permitted to proceed, subject to the CMA’s approval of the terms of all agreements related to the transfer of the CI business to Cochlear. As on August 2, 2023, CMA proposes to accept the attached proposed Final Undertakings; and proposed Final Undertakings seek to address the SLC identified in the Report and any adverse effects resulting from the SLC. As of August 15, 2023, the acquisition is expected to complete by end December 2023. AS of October 9, 2023, European Commission approved the acquisition of Oticon Medical. As of February 19, 2024, the acquisition is expected to complete by the end of June 2024. As of April 4, 2024, Australian Competition and Consumer Commission decided not to oppose the acquisition of Oticon Medical. Ash Chandhok Tiwari of Baker & Mckenzie LLP acted as legal; advisor to Cochlear. Cochlear Limited (ASX:COH) completed the acquisition of Oticon Medical A/s from Demant A/S (CPSE:DEMANT) on May 21, 2024. The transaction has got all the regulatory and customary closing conditions fulfilled.
お知らせ • Apr 23Cochlear Limited Announces Company Secretary ChangesCochlear Limited announced the appointment of Ms Kristy Jo and Mr. Rob McGrory each as Company Secretary, effective 22 April 2024. These appointments follow the disclosure at the 2023 Annual General Meeting of the pending retirement of Mr. Ray Jarman as Company Secretary, which is effective 22 April 2024. Ms Jo is now the person responsible for communications with the ASX under Listing Rule 12.6.
お知らせ • Apr 20Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-OldCochlear Limited obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™? Osia System from 12 years-old to 5-years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The Osia System is a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the innerear (cochlea). It is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. Now children as young as 5 will be able to have full access to the Osia System's unique technology that is optimized to deliver high power and clarity, especially in high-frequency sounds, which are important for hearing what others are saying. Adrian was diagnosed with hearing loss at age 4 and started with the Baha® Sound Processor with a Baha Softband before transitioning to the Osia System at age 6. The Osia System has been shown to provide clinically significant improvements in high frequency hearing for children.
お知らせ • Aug 19Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 TCochlear Limited introduced its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The new Osia System offers the proven benefits as the current version: excellent hearing outcomes, ease of use, discreetness and reliability. With the introduction of the OSI300 Implant, it is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. This new patient benefit is made possible by combining the unique properties of the Osia System's Piezo Power™ transducer, which does not contain magnetic material, and the next generation in implant magnet technology. The OSI300 Implant is specifically designed to support access to MRI with no performance degradation after MRI exposure, as there is nothing to be demagnetized as in an electromagnetic transducer. Unlike an axial magnet, which is found in most bone conduction implants and is unsuitable for a patient undergoing an MRI examination at 3.0 T, the OSI300 uses a diametric magnet that sits within a casing and rotates to align with the magnetic field of the MRI machine. The next generation of the Osia System will be available in clinics across the United States this fall and is currently being reviewed by Health Canada. Availability in other countries is subject to regulatory approvals.
お知らせ • Aug 15Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024Cochlear Limited announced that they will report fiscal year 2024 results on Aug 15, 2024
お知らせ • Jul 18Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023Cochlear Limited announced that Non-executive Director Andrew Denver has advised his intention to retire from the Cochlear Board at the end of the next annual general meeting which will be held on 17 October 2023. Mr. Andrew Denver joined the Cochlear Board on 1 February 2007 and has served as a member of the Audit and Risk, Medical Science, Nomination and Product & Services Innovation Committees.
Upcoming Dividend • Mar 14Upcoming dividend of AU$1.55 per share at 1.3% yieldEligible shareholders must have bought the stock before 21 March 2023. Payment date: 14 April 2023. Payout ratio is a comfortable 68% and the cash payout ratio is 76%. Trailing yield: 1.3%. Lower than top quartile of Mexican dividend payers (6.0%). Lower than average of industry peers (1.8%).
Recent Insider Transactions • Mar 08Independent Non-Executive Director recently bought Mex$358k worth of stockOn the 6th of March, Michael J. Del Prado bought around 132 shares on-market at roughly Mex$2,714 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Mex$6.3m more in shares than they have sold in the last 12 months.
お知らせ • Feb 16+ 1 more updateCochlear Limited Provides Earnings Outlook for the Year 2023Cochlear Limited provided earnings outlook for the year 2023. For the period, the company continue to expect to deliver underlying net profit of $290-305 million, a 5-10% increase on FY22 underlying net profit, an increase of 8-13% when adjusted for the increase in cloud computing-related expenses.
お知らせ • Nov 16Cochlear Limited, Annual General Meeting, Oct 17, 2023Cochlear Limited, Annual General Meeting, Oct 17, 2023.
Recent Insider Transactions • Oct 25Non-Executive Independent Director recently bought Mex$315k worth of stockOn the 24th of October, Karen Lee Penrose bought around 128 shares on-market at roughly Mex$2,464 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Mex$597k. Insiders have collectively bought Mex$3.2m more in shares than they have sold in the last 12 months.
Upcoming Dividend • Sep 15Upcoming dividend of AU$1.45 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 17 October 2022. Payout ratio is a comfortable 68% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Mexican dividend payers (6.4%). Lower than average of industry peers (1.7%).
Recent Insider Transactions • Aug 26Independent Non-Executive Director recently bought Mex$592k worth of stockOn the 24th of August, Michael Daniell bought around 200 shares on-market at roughly Mex$2,960 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Mex$1.4m more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$4.40 (vs AU$4.93 in FY 2021)Full year 2022 results: EPS: AU$4.40 (down from AU$4.93 in FY 2021). Revenue: AU$1.65b (up 10% from FY 2021). Net income: AU$289.1m (down 11% from FY 2021). Profit margin: 18% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 5.4%, compared to a 18% growth forecast for the Medical Equipment industry in Mexico.